

Aniek J G Even

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2821387/publications.pdf>

Version: 2024-02-01

20
papers

3,932
citations

623574

14
h-index

752573

20
g-index

20
all docs

20
docs citations

20
times ranked

5747
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiomics: the bridge between medical imaging and personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 749-762.	12.5	3,216
2	Decision support systems for personalized and participative radiation oncology. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 131-153.	6.6	113
3	Decision Support Systems in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-9.	1.0	85
4	<i>In Vivo</i> Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. <i>Clinical Cancer Research</i> , 2014, 20, 6389-6397.	3.2	81
5	PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. <i>Radiotherapy and Oncology</i> , 2015, 116, 281-286.	0.3	64
6	Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 240-248.	3.3	64
7	Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. <i>Acta Oncologica</i> , 2015, 54, 1289-1300.	0.8	59
8	PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 267-273.	0.3	48
9	Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. <i>Oncotarget</i> , 2017, 8, 3870-3880.	0.8	48
10	Clustering of multi-parametric functional imaging to identify high-risk subvolumes in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 379-384.	0.3	23
11	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. <i>Radiotherapy and Oncology</i> , 2020, 153, 97-105.	0.3	19
12	Impact of SBRT fractionation in hypoxia dose painting – Accounting for heterogeneous and dynamic tumor oxygenation. <i>Medical Physics</i> , 2019, 46, 2512-2521.	1.6	17
13	Miniaturized Electronic Circuit Design Challenges for Ingestible Devices. <i>Journal of Microelectromechanical Systems</i> , 2020, 29, 645-652.	1.7	16
14	Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT. <i>Acta Oncologica</i> , 2017, 56, 1591-1596.	0.8	15
15	High-dose-rate prostate brachytherapy based on registered transrectal ultrasound and in-room cone-beam CT images. <i>Brachytherapy</i> , 2014, 13, 128-136.	0.2	13
16	Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy – the influence of the choice of the reference region and conversion function. <i>Acta Oncologica</i> , 2017, 56, 819-825.	0.8	13
17	[18F]-HX4 PET/CT hypoxia in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy: Prognostic results from two prospective trials. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 9-15.	0.9	12
18	Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 49-55.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription. <i>Acta Oncologica</i> , 2018, 57, 485-490.	0.8	8
20	The promise of multiparametric imaging in oncology: how do we move forward?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1195-1198.	3.3	7